Results from a recent study suggest that multiple myeloma patients whose monoclonal (M) protein levels continue to decrease after 100 days following stem cell trans­planta­tion may experience improved survival.

Both progression-free survival and overall survival were longer in patients who showed such a continued response without additional therapy after autologous stem cell trans­planta­tion (using their own cells).

“This study confirms the observation that the depth of response continues to improve after trans­plant,” said the study’s lead investigator Dr. Shaji Kumar from the Mayo Clinic. “It is of particular importance to patients who …